{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:40:57Z","timestamp":1784259657562,"version":"3.55.0"},"reference-count":11,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Special fund of the National Clinical Key Specialty Construction Program, P. R. China"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Medicine High Impact Case Reports"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>Histiocytic sarcoma (HS) is a rare hematopoietic neoplasm with an aggressive clinical course and a poor response to conventional chemotherapy. Currently, no standard treatment paradigms are available. Herein, we present a case of de novo HS treated with pembrolizumab combined with a GDP regimen (gemcitabine, cisplatin, and dexamethasone) that resulted in sustained complete remission with progression-free survival exceeding 4 years. Immunohistochemical analysis demonstrated significant overexpression of programmed death ligand 1 (PD-L1) on biopsy samples. Additionally, fluorescence in situ hybridization (FISH) with a JAK-2 probe indicated 9p24.1 amplification, suggesting reliance on the JAK-STAT pathway. Polymerase chain reaction (PCR) analysis did not reveal any BRAF-V600 mutations. Consequently, an immune checkpoint inhibitor (ICI) was administered alongside chemotherapy, resulting in sustained complete remission and progression-free survival for over 4 years. Our findings suggest that a combination of ICI and chemotherapy could represent a promising therapeutic approach for HS.<\/jats:p>","DOI":"10.1177\/23247096241274561","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T02:41:25Z","timestamp":1725072085000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Pembrolizumab Combined With GDP Regimen Inducing Sustained Remission in Histiocytic Sarcoma: A Case Report"],"prefix":"10.1177","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0493-9539","authenticated-orcid":false,"given":"Jinjie","family":"Gao","sequence":"first","affiliation":[{"name":"Lymphoma Research Center, Peking University Third Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiling","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Jing","sequence":"additional","affiliation":[{"name":"Lymphoma Research Center, Peking University Third Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"key":"bibr1-23247096241274561","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-812495"},{"key":"bibr2-23247096241274561","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0200-x"},{"key":"bibr3-23247096241274561","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1511490"},{"key":"bibr4-23247096241274561","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.179150"},{"key":"bibr5-23247096241274561","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2202-8"},{"key":"bibr6-23247096241274561","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25100"},{"key":"bibr7-23247096241274561","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4378"},{"key":"bibr8-23247096241274561","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-022-00562-x"},{"key":"bibr9-23247096241274561","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2022.2569"},{"key":"bibr10-23247096241274561","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20913"},{"key":"bibr11-23247096241274561","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-535443"}],"container-title":["Journal of Investigative Medicine High Impact Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23247096241274561","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23247096241274561","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23247096241274561","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:04:10Z","timestamp":1777449850000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/23247096241274561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":11,"alternative-id":["10.1177\/23247096241274561"],"URL":"https:\/\/doi.org\/10.1177\/23247096241274561","relation":{},"ISSN":["2324-7096","2324-7096"],"issn-type":[{"value":"2324-7096","type":"print"},{"value":"2324-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"article-number":"23247096241274561"}}